Tenaya Therapeutics Inc (TNYA) News

Tenaya Therapeutics Announces Research Leadership Updates

Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory...

Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit

SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites...

Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting

SOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Initial Data from Ongoing MyPeak™-1 Phase 1b of TN-201 for MYBPC3-associated HCM Expected in Second Half of...

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine

TN-401 AAV9-Based Gene Therapy Being Developed to Treat the Underlying Cause of PKP2-associated Arrhythmogenic...

Form 4 - Statement of changes in beneficial ownership of securities

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Tenaya Therapeutics Announces Publication of Preclinical HDAC6 Inhibitor Data for Heart Failure with Preserved Ejection Fraction in Nature Communications

Highly selective Small Molecule HDAC6 Inhibitor Effectively Reversed Heart Failure and Improved Diastolic Heart...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report